232 research outputs found
Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?
TNM post-surgical staging is considered to be one of the most powerful prognosticators for colorectal carcinoma. Although patient survival mostly decreases concomitantly to stage increase, in a percentage of cases TNM stage appears only to express the anatomic extent of the neoplasia with no correlation with clinical outcome. Thais, the identification of additional prognostic markers for colorectal cancer is required. Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein that appears to play an important role in colorectal cancer progression. In order to evaluate whether NGAL expression may be considered as a predictor of colorectal cancer progression, we analyzed its correlation with clinicopathological characteristics, as well as with patient progression-free survival in a series of surgically resected colorectal carcinomas. A variable NGAL immunoexpression was found in 24 out of the 64 analyzed cases. When only the positive cases were considered, a significant association was found between a high NGAL expression and the presence of distant metastases or high tumor stage. In addition, the presence of NGAL was a significant negative prognostic marker correlated with a shorter progression-free survival in stage I colorectal carcinoma, but not in the remaining TNM stages. If our findings are confirmed in more extensive analyses on stage I colorectal carcinoma, NGAL assessment may be used in order to select those patients with a higher progression risk and to submit them to adjuvant therapies useful to prevent adverse outcome
NGAL immunohistochemical expression in brain primary and metastatic tumors
A significant association has been recently shown between the expression of neutrophil gelatinase-associated lipocalin (NGAL) in tumors and its urinary levels. Thus NGAL urinary detection has been proposed as a method for the early diagnosis of brain tumors. In view of this, the objective of this study was to investigate whether NGAL expression differs according to brain tumor type or in primary vs. metastatic brain neolasias. 42 surgically resected formalin fixed and paraffin embedded neoplasias, including 15 cases of brain metastasis and 27 cases of primary central nervous system (CNS) tumors (11 meningiomas; 1 pilocytic astrocytoma, 2 diffuse astrocytomas, 2 oligoastrocytomas, 2 oligodendrogliomas, 1 anaplastic oligoastrocytoma, 7 glioblastomas, 1 ependymoma) were submitted to the immunohistochemical procedure. Sections were incubated overnight with the primary antibody against NGAL. NGAL staining was found in all the analyzed glioblastomas and in the anaplastic oligoastrocytoma. No NGAL immuno-expression was evidenced in all the other cases. A statistically significant correlation was demonstrated between NGAL presence and high proliferation index in the primary tumors. In conclusion, our findings suggest that NGAL expression is restricted to high grade gliomas among primary brain tumors, and that brain metastases do not express this protein. Considering the correlation between NGAL expression in tumors and its urinary levels, if our observations will be further validated, NGAL urinary detection might be used as an additional tool in the pre-surgical definition of brain lesions involving difficult differential diagnosis
Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density
Adiponectin (ApN) is a 30 kDa adipo-cytokine with anti-angiogenic effects. The expression of its receptors, Adipo-R1 and Adipo-R2, has been reported in colorectal cancer tissue and cell lines, but ApN expression in this neoplasia has not been investigated until now. In the present study, we aimed to analyse ApN expression and its eventual correlations with the clinico-pathological parameters and with the quantity of neo-angiogenesis, as reflected by the microvessel density (MVD), in human sporadic surgically resected colorectal carcinomas
Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas
Since it has recently been reported that caveolin-1 (cav-1) may favor the progression of prostatic and renal cancers by stimulating tumor neoangiogenesis, we thought it of interest to analyze the correlation between cav-1 expression and tumor microvessel density (MVD) in meningiomas. In the present study we quantified cav-1 expression by immunohistochemistry and used CD105 immunohistochemical staining to measure MVD. Sixty-two formalin-fixed, paraffin-embedded, surgically resected meningiomas were submitted to the analysis. On the basis of cav-1 immuno-expression, cases were subdivided into meningiomas displaying a low (n = 34) and a high (n = 28) cav-1 immuno-expression, respectively. Mann-Whitney test showed that a significantly higher MVD was present in the cases with a high cav-1 expression than in those with a low expression (mean 24.44 vs. 41.28 microvessels/mm(2)) (P = 0.0001). Moreover, Spearman test revealed a significant positive correlation between cav-1 rate of expression and MVD counts in the meningiomas of our series (r = 0.390; P = 0.0023). Therefore, our study demonstrates the existence of an association between cav-1 expression and neoangiogenesis in meningiomas, suggesting that cav-1 may mediate the progression of these tumors by stimulating the angiogenic process. Besides, it is known that the progression of meningiomas is paralleled by an increase in MVD. The clarification of cav-1 role in the neoangiogensis of meningiomas may open new insights about the possibility of novel therapeutic strategies in these neoplasias
Refertazione istopatologica e fattori prognostici del carcinoma mammario: requisiti minimi
The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma
Background: Adiponectin (ApN) is a 30 kDa adipocytokine which mediates an antineoplastic effect after binding to its receptors, Adipo-R1 and Adipo-R2. The expression of these receptors has been documented in gastric cancer (GC) cell lines, but only a few data exist on their expression in GC neoplastic tissue.Aim: To investigate the expression of Adipo-R1 and Adipo-R2 in a series of surgically resected GCs and to assess its association with various tumour clinicopathological characteristics as well as with patient survival.Methods: Forty-nine surgically resected GCs were submitted to immunohistochemical assays for Adipo-R1, Adipo-R2 and ApN.Results: Adipo-R1 and Adipo-R2 immunoexpression was found in 22/49 GCs and in intestinal metaplasia areas near the tumours, whereas only slight immunoreactivity for these proteins was found in adjacent normal gastric epithelium. No ApN expression was encountered in any of the cases analysed. Adipo-R1/Adipo-R2 expression was significantly associated with an intestinal histotype of the tumours and with longer overall survival of the patients.Conclusions: Intestinal-type GCs often express AdipoR1/R2 in association with a better prognosis. The presence of these receptors could be exploited for novel anticancer therapies based on ApN addition in GC
Immunoexpression of lactoferrin in human sporadic renal cell carcinomas
By immunohistochemistry, lactoferrin (Lf) expression was retrospectively investigated in 40 formalin-fixed paraffin-embedded kidney samples, obtained at surgery from an equal number of patients. Histologically, 28 cases were clear cell carcinomas (CCC), 7 papillary carcinomas (PC) and 5 chromophobe carcinomas (CC). Ten specimens of unaffected renal parenchyma were utilized as tissue control. On 4-microm thick sections, the Lf immunoreactivity was revealed either by a rabbit polyclonal or mouse monoclonal anti-human Lf antisera; the quantification of Lf immunoreactivity was performed using an intensity-distribution (ID) score. A positive immunoreaction by both anti-Lf antibodies was found in 62.5% (25/40) of RCC, mainly evident and diffuse by monoclonal antiserum. The immunoreactivity was observed in the cytoplasmic boundary of neoplastic cells in CCC and PC, while in CC Lf showed a diffuse granular cytoplasmic localization. Moreover, significant differences in Lf ID score were found among CCC and non-CCC variants (P<0.00001), the former showed a lower score; no relationships between immunohistochemical data and the sex or age of patients, grade of RCC, stage of the disease or degree of terminal anemia were encountered. Normal unaffected tubular structures were positive for Lf; glomeruli were unstained. The reduced Lf immunoexpression in some CCC may be because of the down-regulation of Lf gene due to the frequent deletion of 3p regions reported in this RCC variant
- …
